Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13700853 | 0.86 | TDP1 (0.39) | SMN1; SMN2POLBTDP1RAB9AMEN1 | |
| SCHEMBL18349239 | 0.82 | ALDH1A1 (0.48) | APPSMN1; SMN2CYP1B1RAB9AMEN1 | |
| SCHEMBL18349234 | 0.74 | CHAT (0.42) | CYP19A1MAOAMAOBAPPSMN1; SMN2 | |
| SCHEMBL18349240 | 0.73 | CYP19A1 (0.47) | CYP19A1MAOAMAOBAPPCYP1B1 | |
| SCHEMBL13464630 | 0.73 | ALDH1A1 (0.40) | SMN1; SMN2POLBMEN1MAPTKMT2A | |
| SCHEMBL18349232 | 0.72 | RAB9A (0.41) | CYP19A1MAOAMAOBSMN1; SMN2POLB | |
| SCHEMBL18349198 | 0.71 | MAPT (0.46) | APPSMN1; SMN2CYP1B1RAB9AMEN1 | |
| SCHEMBL9509301 | 0.69 | TDP1 (0.39) | SMN1; SMN2TDP1ALDH1A1LMNAHTT | |
| SCHEMBL7534626 | 0.67 | CYP19A1 (0.52) | CYP19A1MAOAMAOBAPPPOLB | |
| SCHEMBL7534630 | 0.67 | CYP19A1 (0.52) | CYP19A1MAOAMAOBAPPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | CYP19A1 3504/4885MAOA 2682/4885MAOB 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.